Three patients with known germline mutations in either BRCA1/2 had tumour profiling performed on the AmpliSeq Cancer Hotspot V2 test panel, which did not include BRCA1/2, and thus, somatic BRCA alterations were not identified. The gene discussed is BRCA1; the disease is neoplasm.